Moleculin closes Part A enrollment in MIRACLE AML trial at 89, one subject still in screening
Moleculin Biotech reported Part A enrollment complete for its Phase 2/3 MIRACLE trial in relapsed/refractory AML, with data expected in the first quarter of 2027.
Moleculin Biotech's update this week centered on its pivotal AML trial for Annamycin.
- MIRACLE is a Phase 2/3 trial testing Annamycin plus cytarabine against cytarabine plus placebo in adults with relapsed or refractory acute myeloid leukemia. The company said it completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML), with 89 subjects enrolled and an additional subject currently in screening.1 The company said it remains on track for its planned comprehensive data readout of Part A in the first quarter of 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.